Citation Report

List of articles citing

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol

DOI: 10.2174/1389557518666180423111442
Mini-Reviews in Medicinal Chemistry, 2019, 19, 165-176.

#	Paper	IF	Citations
21	Cholesterol as an Endogenous ERR Agonist: A New Perspective to Cancer Treatment. *Frontiers in Endocrinology*, **2018**, 9, 525	5.7	24
20	Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies. *IUBMB Life*, **2019**, 71, 1221-1229	4.7	15
19	PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 7310-7319	5.6	19
18	Scavenger Receptors as Biomarkers and Therapeutic Targets in Cardiovascular Disease. *Cells*, **2020**, 9,	7.9	1
17	Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design. *Journal of Medicinal Chemistry*, **2020**, 63, 13796-13824	8.3	15
16	Pharmacogenetics of Statin-Induced Myotoxicity. *Frontiers in Genetics*, **2020**, 11, 575678	4.5	15
15	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. *Pharmacoeconomics*, **2020**, 38, 1095-1113	4.4	11
14	Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy. *Pharmacology Research and Perspectives*, **2020**, 8, e00584	3.1	9
13	Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9. *Journal of Medicinal Chemistry*, **2021**, 64, 10834-10848	8.3	3
12	Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor. *Pharmacological Research*, **2020**, 158, 104847	10.2	16
11	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. *Clinical Science*, **2020**, 134, 1775-1799	6.5	9
10	Assessing drug target suitability using TargetMine. *F1000Research*, **2019**, 8, 233	3.6	2
9	Assessing drug target suitability using TargetMine. *F1000Research*, **2019**, 8, 233	3.6	1
8	A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 16770-16800	8.3	6
7	Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.. *Frontiers in Oncology*, **2022**, 12, 803473	5.3	6
6	Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank.. *Nature Genetics*, **2022**,	36.3	4
5	Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2022**, 1	3.4	0

4	Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA Adverse Event Reporting System. *British Journal of Clinical Pharmacology*,	3.8	1
3	Effects of Loading-Dose Statins Combined with PCSK9 Inhibitor Pre-Treatment before Primary Percutaneous Coronary Intervention on the Short-Term Prognosis in Patients with ST-Segment Elevation Myocardial Infarction. **2022**,		0
2	Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis. 14,		0
1	Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.		0